Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. (Q50893620)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

title

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

0 references

Marja-Riitta Taskinen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

author name string

A Hiukka

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

E Leinonen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

M Jauhiainen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

J Sundvall

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

C Ehnholm

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

A C Keech

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

publication date

26 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

2067-2075

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17653691 AND SRC:MED&resulttype=core&format=json

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

2 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007/S00125-007-0751-8

Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S00125-007-0751-8

Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates

21 January 2018

1 reference

12 December 2020

Determination of human plasma phospholipid transfer protein mass and activity

1 reference

12 December 2020

Human plasma lecithin-cholesterol acyltransferase. An elucidation of the catalytic mechanism

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

12 December 2020

Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages

1 reference

12 December 2020

Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III

1 reference

12 December 2020

Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome

1 reference

12 December 2020

Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans

1 reference

12 December 2020

Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.

1 reference

12 December 2020

The rationale for using apoA-I as a clinical marker of cardiovascular risk

1 reference

12 December 2020

LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins.

1 reference

12 December 2020

Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes

1 reference

12 December 2020

Improved estimation of cholesteryl ester transfer/exchange activity in serum or plasma.

1 reference

12 December 2020

Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial

1 reference

12 December 2020

Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.

1 reference

12 December 2020

Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia

1 reference

12 December 2020

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus

1 reference

12 December 2020

Relationship between postheparin plasma lipases and high-density lipoprotein cholesterol in different types of diabetes

1 reference

12 December 2020

The impact of phospholipid transfer protein (PLTP) on HDL metabolism

1 reference

12 December 2020

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

1 reference

12 December 2020

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

12 December 2020

Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days

1 reference

12 December 2020

The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]

1 reference

12 December 2020

Antiatherogenic small, dense HDL--guardian angel of the arterial wall?

1 reference

12 December 2020

High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study

1 reference

12 December 2020

Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease

1 reference

12 December 2020

Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients

1 reference

12 December 2020

A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians

1 reference

12 December 2020

Protein measurement with the Folin phenol reagent

1 reference

12 December 2020

Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes

1 reference

12 December 2020

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

1 reference

12 December 2020

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

1 reference

12 December 2020

Diabetic dyslipidaemia: from basic research to clinical practice.

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020